Case Report: Omalizumab-Associated Hair Loss: A Case of Eyebrow Alopecia Areata, Literature Review and FAERS Database Analysis

This case report describes a 52-year-old female who developed eyebrow alopecia areata after 12 weeks of omalizumab treatment for chronic spontaneous urticaria. Her eyebrows regrew after 28 weeks with the use of topical tacrolimus, despite continuing omalizumab. Analysis of 756 cases from the FAERS database and a literature review suggest that omalizumab may induce alopecia, particularly in females aged 18-60, although a direct cause-effect relationship is difficult to establish. Alopecia areata appears to be a less common but potentially transient side effect. The study emphasizes the need for clinicians to recognize this potential adverse effect to improve patient counseling and treatment planning.